RJH Biosciences Inc. to Receive Funding Under Grand Challenges Explorations Initiative
EDMONTON, Alberta--(BUSINESS WIRE)--Nov 14, 2019--
RJH Biosciences Inc. has announced a grant from the Bill & Melinda Gates Foundation to develop a new device to enable ‘Immunotherapy On-the-Go’. RJH Biosciences Inc., a privately held biotech company in Edmonton, Alberta, will pursue a Phase I Project under the Grand Challenges Explorations initiative to develop a new mode of immunotherapy.
Recently emerging immunotherapy has excited the medical field by creating novel forms of therapy, especially for deadly cancers. Immunotherapy is now being explored in the treatment of different diseases, with hundreds of clinical immunotherapy studies underway around the world. Current immunotherapy relies on viruses to manipulate and stimulate the immune system by modifying patients’ cells outside the body. This protocol is costly ($500,000 per treatment is typical) and requires extensive facilities to undertake the therapy. As a result, this kind of therapy is not accessible to most patients, especially in the Developing World.
Using US$100,000 in seed funding from the foundation, RJH Biosciences has committed to developing a convenient immunotherapy approach that does not require extensive instrumentation and can be easily deployed to patients around the world. “We are encouraged with the decision of the Bill & Melinda Gates Foundation to support our promising approach and move our concept forward”, said Dr. Hasan Uludag, a biomedical engineer and the President of RJH Biosciences. The funded project is further intended to foster innovation to solve key global health and development problems.
About RJH Biosciences Inc.
RJH Biosciences Inc. is a University of Alberta spin-off company focusing on development of transfection reagents and delivery agents for nucleic acids. The goal of the company is to create effective therapies using nucleic acids to realize the dream of gene medicine. The company distributes its products via its website and undertakes projects on new medical treatments. More information about the company can be found at www.rjhbiosciences.com.
About Grand Challenges Explorations
Grand Challenges Explorations is a US$100 million initiative funded by the Bill & Melinda Gates Foundation. Launched in 2008, over 1,480 projects in more than 70 countries have received Grand Challenges Explorations grants. The grant program is open to anyone from any discipline and from any organization. The initiative uses an agile, accelerated grant-making process with short two-page online applications and no preliminary data required. Initial grants of US$100,000 are awarded two times per year. Successful projects have the opportunity to receive a follow-on grant of up to US$1 million.
This public release contains forward-looking statements about potential future achievements and deliverables. The achievement or deliverables covered by such forward-looking statements involves risks, uncertainties and assumptions. These risks and uncertainties include, among other things, the company’s ability to achieve certain technical milestones, to secure resources, including financial, to continue operations and the company’s ability to realize benefits from strategic partnerships. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, the company’s results could differ materially from the results expressed or implied by the forward-looking statements here. More information about this press release could be obtained by contacting RJH Biosciences Inc. at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191114005874/en/
CONTACT: Anyeld Ubeda
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH SCIENCE RESEARCH
SOURCE: RJH Biosciences Inc.
Copyright Business Wire 2019.
PUB: 11/14/2019 04:10 PM/DISC: 11/14/2019 04:10 PM